Inside Information: Optomed Plc successfully completed a directed share issue, raising approximately 6.0 million euros
A total of 1,760,000 Shares were subscribed for in the share issue. The Company expects to receive gross proceeds of approximately 6.0 million euros as a result of the share issue. Investors include experienced and institutional investors from Finland.
As previously announced, the Company successfully launched Optomed Lumo, a handheld fundus camera, in the third quarter of 2025. Positive early feedback reinforces the Company’s position in the rapidly growing oculomics market. Optomed Lumo has received FDA PJZ classification, which allows it to be marketed in the United States as a Class II fundus camera without a lengthy approval process. However, for the Company to obtain FDA approval for the sale and marketing of Optomed Lumo in conjunction with diabetic retinopathy AI (such as AEYE Health used in the Optomed Aurora AEYE camera), the Company must conduct clinical trials. In the current competitive environment, securing additional funding quickly is critical for the Company to scale up its production, initiate regulatory approval processes, and increase sales of its products with the aim of improving the Company’s net cash flow in a sustainable manner.
The subscription price was 3.40 euros per Share. The subscription price corresponds to a discount of approximately 11.1 percent compared to the closing price of the Company’s share on December 10, 2025. The subscription price has been determined in negotiations corresponding to a book-building process, involving a limited number of institutional and experienced investors. Investors have been identified based on their investment potential, knowledge of the Company and its industry, and familiarity with the Finnish market. The procedure aimed to ensure the realization of the financing arrangement and the market-based nature of the subscription price. The subscription price will be recorded in its entirety in the Company’s fund for invested unrestricted equity.